The company submitted a supplemental new drug application (sNDA) to teh FDA for Stivarga tablets for the second-line systemic treatment of patients with unresectable hepatocellular carcinoma (uHCC). The drug
Cherish, the study assessing Spinraza in later-onset SMA, found that children receiving the drug experienced a highly statistically-significant improvement in motor function compared to those who did not
The company will buy nearly seven million newly issued Aimmune’s common stock shares each priced at $19.20. Both Aimmune and Nestlé Health Science have also agreed to collaborate on
The approval of the company’s supplemental Biologics License Application makes it the first and only systemic therapy to treat pediatric patients aged 4 to 17 affected by the
The insulin glargine, which has been co-developed by Mylan and Biocon, is used to treat adults with Type 2 diabetes and adults and paediatric patients with type 1
Researchers from the Massachusetts Institute of Technology (MIT), the University of Brasilia and the University of British Columbia have engineered an antimicrobial peptide that they claim will destroy
The biotechnology company will use the proceeds from financing to accelerate and expand pipeline of oncolytic viral immunotherapies. Turnstone CEO Sammy Farah said: “We are taking a rapid and expansive
The trial will explore whether the use of the citrate anticoagulant extends the extracorporeal circuit life in acute kidney patients undergoing continuous renal replacement therapy (CRRT). The first
The drug is intended to be used in combination with letrozole as a first-line treatment of postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-)
According to the people familiar with the matter, Japan’s Takeda Pharmaceutical is expected to acquire Salix gastroenterology business unit for around $10bn. In April 2015, Valeant acquired Salix
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.